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patients with a recent ischemic stroke/TIA. The purpose of this study was to esti-
mate the cost-effectiveness of two screening methods for detection of silent AF, 
brief intermittent long-term ECG recordings at regular time intervals and short-
term 24-hours continuous ECG (Holter-ECG) and to compare them to a no screening 
alternative in patients with a recent ischemic stroke. Methods: The long-term 
(20 year) costs and effects of brief intermittent long-term ECG recordings at regular 
time intervals and short term continuous ECG are estimated with a decision ana-
lytic model combining the result of a clinical study and epidemiological data. The 
structure of a cost-effectiveness analysis was used in this study. The short term 
decision tree model analyzed the screening procedure until the onset of antico-
agulant treatment. The second part of the decision model follows a Markov design 
simulating the patients for 20 years. Results: Continuous 24 h ECG recording was 
dominated by intermittent ECG due to lower sensitivity and higher costs. The base 
case analysis compared intermittent-ECG screening with no screening of patients 
with recent stroke. The implementation of the screening program on 1000 patients 
resulted in 10,9 avoided strokes and the gain of 29,2 life years or 22,7 QALYs and 
cost savings of € 55 000. ConClusions: Screening of silent AF by intermittent ECG 
recordings in patients with a recent ischaemic stroke is cost-effective use of health 
care resources saving costs, lives and quality of life.
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objeCtives: To estimate the cost-effectiveness of diagnostic pathways for assessing 
patients with ischaemic cardiomyopathy to identify patients with viable myocar-
dium with a view to revascularisation. Methods: A decision analytic model was 
developed to estimate the cost-effectiveness of diagnostic strategies for assessing 
patients with ischaemic cardiomyopathy. The different diagnostic pathways were 
applied to a hypothetical cohort of patients with ischaemic cardiomyopathy and the 
probability of successful identification of viable myocardium and non-viable myo-
cardium was determined by the accuracy of the diagnostic pathway. It was assumed 
that patients diagnosed with viable myocardium would be managed promptly by 
revascularisation and that the patients diagnosed with non-viable myocardium 
would be on medical therapy. The model assigned each patient a risk of death and 
rehospitalisation depending upon whether they are truly viable and whether they 
had revascularisation or not. Each patient then accrued lifetime QALYs. Health care 
costs were also accrued through measuring diagnostic costs and treatment costs, 
depending on the pathway and their treatment status. Results: All the diagnostic 
pathways are cost-effective when compared with no testing at current NICE thresh-
old, this suggests that all the current services for diagnosing viable myocardium 
are a cost effective use of NHS resources irrespective of the diagnostic pathway 
used. For services that need to decide the most cost-effective strategy starting from 
scratch, then Stress CMR is the most cost-effective strategy. ConClusions: There 
are a number of issues with abstracting the data for cost-effectiveness modelling 
of diagnostic tests. For example, the diagnostic accuracy depends upon the type of 
index test, gold standard test and threshold used. Furthermore, the benefits of treat-
ments after diagnosis are not always clear and might be linked to the type of diag-
nostic test. Appropriate caution needs to be taken when evaluating diagnostic tests.
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objeCtives: Ivabradine is approved by the European Medicine Agency for the treat-
ment of Chronic Heart Failure (CHF) NYHA II to IV class with systolic dysfunction 
in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with 
standard therapy including beta-blocker therapy or when beta-blocker therapy is 
contraindicated or not tolerated. The study objective was to perform a cost-effective-
ness analysis of ivabradine based on the outcomes of the SHIFT clinical trial from 
the perspective of the Irish Health Service Executive (HSE). Methods: A six health 
state Markov model with health states for CHF NYHA classes I to IV, alive, and dead 
was adapted to the Irish health care setting. The economic evaluation compared 
the cost-effectiveness of ivabradine in combination with standard therapy versus 
standard therapy alone. A lifetime horizon was chosen in the base case analysis. 
Costs and effects were discounted at 4% per year. Deterministic and probabilistic 
sensitivity analyses were performed. Health state utilities were estimated from 
EQ-5D index scores obtained from the SHIFT clinical trial. The base case analysis 
was based on heart failure outcomes and associated costs. Results: When used 
in addition to standard therapy, ivabradine increased discounted health care costs 
by € 2169 for a 0.23 QALY gain, resulting in an incremental cost per QALY gained of 
€ 9,426. In no case of the deterministic sensitivity analysis did the cost per QALY 
gained increase above € 20,000. The probability of the cost-effectiveness of ivabradine 
at a willingness to pay threshold of € 45,000 per QALY gained was estimated to be 
approx. 100%. ConClusions: When used in addition to standard therapy, based 
on heart failure outcomes and associated costs, ivabradine had an incremental cost 
per QALY gained of € 9,426 with an approximately 100% probability of being cost-
effective at a willingness to pay threshold of € 45,000 per QALY gained.
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objeCtives: Hypertension affects 41% of male and 31% of female adults in Belgium; 
13% of these are believed to be refractory to standard hypertension treatment (uncon-
practice. A societal perspective incorporated the following indirect costs: formal and 
informal long term care costs for stroke, productivity losses associated with stroke 
and carers, and productivity, out of pocket and travel costs associated with INR 
testing in both metropolitan and rural settings. The opportunity cost of a delayed 
dabigatran PBS listing was estimated over a 2 year period. Estimates were derived 
using the economic model presented to the PBAC. Results: When incorporating a 
societal perspective, dabigatran was cost saving versus both warfarin and the mixed 
comparator. Dabigatran is estimated to save an average of $2,011 and $3,994 per 
patient per year for patients in metropolitan and rural settings respectively com-
pared with current practice. In the more than two years since the initial PBAC rec-
ommendation of dabigatran it is estimated over 150,000 patients have been denied 
affordable access to treatment, resulting in $47.9 million in costs to Medicare, $5.2 
million in patient out of pocket costs and 470,000 hours of lost productivity due to 
avoidable INR testing. Importantly, 4,059 strokes and 902 resultant deaths could have 
been avoided in this time compared to current practice. ConClusions: Dabigatran 
is a cost-effective treatment for stroke prevention in patients with NVAF in Australia 
and is cost saving compared to current therapy (warfarin, aspirin and no treatment) 
when a societal perspective is taken.
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objeCtives: Hypertension represents a major health problem, affecting more than 1 
billion adults worldwide. Irbesartan, an angiotensin II receptor blocker, is considered 
to be a highly effective treatment in the management of hypertension. Therefore 
this study aims to evaluate the efficacy, safety and tolerability profile, as well as 
the cost-effectiveness of irbesartan in the treatment of hypertension. Methods: 
A review of the literature was conducted using the electronic databases Medline, 
Cochrane and HEED of search terms relating to irbesartan efficacy, tolerability and 
cost-effectiveness and the results were synthesized. Results: Findings from the 
present analysis show that irbesartan either as monotherapy or in combination 
with other agents can have significant reductions in Blood Pressure, both systolic 
and diastolic, when compared to other alternative treatment options. Irbesartan 
was also found to have a renoprotective effect, independent of its blood pressure 
lowering effect in patients with type 2 diabetes and nephropathy. Irbesartan also 
delayed onset of end-stage renal disease (ESRD) and reduced the cumulative inci-
dence of ESRD. Furthermore, Irbesartan demonstrated an excellent safety and toler-
ability profile. Overall adverse event incidence with irbesartan was comparable with 
other antihypertensive drugs. Most common adverse events were headache, fatigue 
and dizziness. In terms of economic analyses, compared to other antihypertensive 
therapy alternatives, irbesartan increased life expectancy and lead to substantial 
cost savings. ConClusions: Evidence indicates that treating patients with hyper-
tension alone or with type II diabetes and nephropathy, can control hypertension, 
prolong life and reduce costs, in relation to other existing alternatives.
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Post thrombotic syndrome (PTS) is a chronic condition that develops in up to 50% of 
patients after deep vein thrombosis and is characterized by debilitating complaints 
of the leg. Two randomized controlled trials (RCT) showed that elastic compression 
stocking (ECS) therapy for 2 years after DVT reduces the PTS incidence by approxi-
mately 50%. A recent management study showed that tailored duration of ECS ther-
apy on individual patient characteristics may result in a reduction of ECS therapy of 
18 months for 50% of patients with an even lower incidence of PTS. However, these 
results may be biased. objeCtives: To explore the cost-effectiveness of individually 
tailored ECS therapy (IND) compared with a standard duration of 2 years ECS therapy 
(STANDARD), from a health care perspective in order to inform the design of an RCT 
comparing the two treatment options. Methods: A decision-analytic probabilistic 
Markov model with lifelong time horizon was used. Health states in the model are: 
No PTS with stocking, No PTS without stocking, Mild to moderate PTS, Severe PTS, 
and Death. Transition probabilities, costs, and utilities were obtained from litera-
ture. The incidence of PTS was taken from the trials (STANDARD: 2-year incidence 
24.5%) and the management study (IND: 2-year incidence 21.1%). The delta for non-
inferiority of a future RCT was determined, and uncertainty was assessed in value 
of information analyses. Results: Based on current evidence IND saves € 2,292 and 
gains 0.14 quality adjusted life years (QALY) per patient compared to STANDARD. 
This result is however highly uncertain, and future research is valuable. The savings 
of IND amount to € 306 when assuming equal incidence of PTS. If PTS incidence is 
7% higher in IND, the treatment seizes to be cost-effective. ConClusions: Based 
on current limited evidence, IND may dominate STANDARD. Future research is 
worthwhile, and may be informed by this modeling study.
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objeCtives: Prolonged brief intermittent arrhythmia screening has been suggested 
to substantially improve detection of silent paroxysmal atrial fibrillation (AF) in 
